MX2016016318A - Proceso para la purificacion de la proteina de fusion. - Google Patents
Proceso para la purificacion de la proteina de fusion.Info
- Publication number
- MX2016016318A MX2016016318A MX2016016318A MX2016016318A MX2016016318A MX 2016016318 A MX2016016318 A MX 2016016318A MX 2016016318 A MX2016016318 A MX 2016016318A MX 2016016318 A MX2016016318 A MX 2016016318A MX 2016016318 A MX2016016318 A MX 2016016318A
- Authority
- MX
- Mexico
- Prior art keywords
- tnfr
- fusion protein
- purification
- present
- hcp
- Prior art date
Links
- 108091006020 Fc-tagged proteins Proteins 0.000 title abstract 4
- 238000000746 purification Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 238000001042 affinity chromatography Methods 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 238000012434 mixed-mode chromatography Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
- B01D15/203—Equilibration or regeneration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/30—Partition chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3847—Multimodal interactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1919MU2014 | 2014-06-13 | ||
| PCT/IB2015/054494 WO2015189832A1 (en) | 2014-06-13 | 2015-06-13 | Process for the purification of tnfr:fc fusion protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016016318A true MX2016016318A (es) | 2017-06-12 |
Family
ID=53524922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016318A MX2016016318A (es) | 2014-06-13 | 2015-06-13 | Proceso para la purificacion de la proteina de fusion. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10556942B2 (enExample) |
| EP (1) | EP3155009A1 (enExample) |
| JP (1) | JP6747985B2 (enExample) |
| CN (1) | CN106536565A (enExample) |
| AU (1) | AU2015273049B2 (enExample) |
| BR (1) | BR112016029157A8 (enExample) |
| CA (1) | CA2951766A1 (enExample) |
| MA (1) | MA40232A (enExample) |
| MX (1) | MX2016016318A (enExample) |
| PH (1) | PH12016502482A1 (enExample) |
| RU (1) | RU2698654C2 (enExample) |
| WO (1) | WO2015189832A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| WO2016149139A1 (en) * | 2015-03-13 | 2016-09-22 | Samsung Bioepis Co., Ltd. | Anti-tnf-alpha polypeptide composition and use thereof |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| JP7106187B2 (ja) | 2016-05-11 | 2022-07-26 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを保存する方法 |
| ES2909833T3 (es) | 2016-05-11 | 2022-05-10 | Cytiva Bioprocess R & D Ab | Método de limpieza y/o desinfección de una matriz de separación |
| ES2874974T3 (es) | 2016-05-11 | 2021-11-05 | Cytiva Bioprocess R & D Ab | Matriz de separación |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| ES2887046T3 (es) * | 2017-08-17 | 2021-12-21 | Just Evotec Biologics Inc | Método de purificación de proteína glicosilada a partir de galectinas de las células hospedadoras y otros contaminantes |
| EP3676281A1 (en) * | 2017-08-30 | 2020-07-08 | Ares Trading S.A. | Method for purifying proteins |
| US11952399B2 (en) * | 2018-12-18 | 2024-04-09 | Amgen Inc. | Methods for purifying proteins |
| US20220098279A1 (en) * | 2019-01-30 | 2022-03-31 | Amgen Inc. | Aflibercept attributes and methods of characterizing and modifying thereof |
| KR102286892B1 (ko) * | 2019-07-08 | 2021-08-06 | 삼천당제약주식회사 | 안과용 단백질 제제의 정제방법 |
| CN112876567A (zh) * | 2019-11-29 | 2021-06-01 | 广东菲鹏制药股份有限公司 | Fc融合蛋白及其纯化方法 |
| EP4118093A4 (en) * | 2020-03-11 | 2024-04-17 | Dr. Reddy's Laboratories Ltd. | METHOD FOR PURIFYING A FC FUSION PROTEIN |
| CN113563469A (zh) * | 2020-04-28 | 2021-10-29 | 江苏中新医药有限公司 | 高回收率纯化阿达木单抗的方法 |
| WO2022234412A1 (en) * | 2021-05-03 | 2022-11-10 | Lupin Limited | A process for purification of fc-fusion proteins |
| AU2022358612A1 (en) * | 2021-09-28 | 2024-04-11 | Kashiv Biosciences, Llc | An improved process of purification of fusion protein |
| EP4408879A4 (en) * | 2021-09-28 | 2025-08-27 | Kashiv Biosciences Llc | IMPROVED PROCESS FOR PURIFYING FUSION PROTEIN |
| WO2023053030A1 (en) * | 2021-09-28 | 2023-04-06 | Kashiv Biosciences, Llc | An improved process for purification of protein |
| WO2023068740A1 (ko) * | 2021-10-19 | 2023-04-27 | 주식회사 알테오젠 | Igg fc 도메인을 가지는 융합 단백질의 정제방법 |
| US20250026784A1 (en) * | 2021-11-29 | 2025-01-23 | Tosoh Corporation | Separation method of antibody |
| CN119060168A (zh) * | 2024-09-26 | 2024-12-03 | 广东丸美生物技术股份有限公司 | 一种具有低电导率的重组胶原蛋白溶液及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2021284C1 (ru) * | 1991-05-30 | 1994-10-15 | Всесоюзный научно-исследовательский институт технологии кровезаменителей и гормональных препаратов | Способ очистки клинических фракций декстрана |
| US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| SI1478394T1 (sl) | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| CA2516518A1 (en) | 2003-02-28 | 2004-09-10 | Lonza Biologics Plc. | Antibody purification by protein a and ion exchange chromatography |
| US8263750B2 (en) * | 2006-03-16 | 2012-09-11 | Amgen Inc. | Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step |
| JP2010501622A (ja) * | 2006-08-28 | 2010-01-21 | アレス トレーディング ソシエテ アノニム | Ｆｃ−融合タンパク質の精製法 |
| US8513393B2 (en) * | 2006-08-28 | 2013-08-20 | Ares Trading S.A. | Process for the purification of Fc-containing proteins |
| EP2203465A1 (en) * | 2007-10-22 | 2010-07-07 | Merck Serono S.A. | Method for purifying an fc-containing protein |
| JP2011514895A (ja) * | 2008-02-29 | 2011-05-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 精製免疫グロブリン融合タンパク質およびその精製方法 |
| CA2739352C (en) * | 2008-10-29 | 2021-07-13 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
| KR101753569B1 (ko) * | 2010-01-22 | 2017-07-04 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｆｃ―함유 단백질을 정제하는 크로마토그래피 방법 |
| EP2723759A4 (en) * | 2011-06-24 | 2015-01-28 | Reddys Lab Ltd Dr | PURIFICATION OF CHIMERIC PROTEIN |
| JP6280499B2 (ja) * | 2011-07-08 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｆｃ融合タンパク質の精製方法 |
| KR101454316B1 (ko) * | 2011-08-17 | 2014-10-27 | 한화케미칼 주식회사 | 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법 |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| AU2013315750B9 (en) | 2012-09-11 | 2018-11-15 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
| CN102911250B (zh) * | 2012-09-29 | 2014-04-16 | 浙江海正药业股份有限公司 | 酸性重组蛋白药物的纯化方法 |
| US9649383B2 (en) * | 2012-11-19 | 2017-05-16 | Merck Sharp & Dohme Corp. | Liquid formulations for TNFR:Fc fusion proteins |
| AU2014240596B2 (en) * | 2013-03-14 | 2018-09-27 | Amgen Inc. | Removal of leaked affinity purification ligand |
| US8946395B1 (en) * | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
-
2015
- 2015-06-13 WO PCT/IB2015/054494 patent/WO2015189832A1/en not_active Ceased
- 2015-06-13 AU AU2015273049A patent/AU2015273049B2/en not_active Ceased
- 2015-06-13 CA CA2951766A patent/CA2951766A1/en not_active Abandoned
- 2015-06-13 CN CN201580038801.XA patent/CN106536565A/zh active Pending
- 2015-06-13 MX MX2016016318A patent/MX2016016318A/es unknown
- 2015-06-13 US US15/318,489 patent/US10556942B2/en active Active
- 2015-06-13 JP JP2016572703A patent/JP6747985B2/ja not_active Expired - Fee Related
- 2015-06-13 MA MA040232A patent/MA40232A/fr unknown
- 2015-06-13 RU RU2017100005A patent/RU2698654C2/ru active
- 2015-06-13 EP EP15734731.1A patent/EP3155009A1/en not_active Withdrawn
- 2015-06-13 BR BR112016029157A patent/BR112016029157A8/pt not_active Application Discontinuation
-
2016
- 2016-12-13 PH PH12016502482A patent/PH12016502482A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016029157A2 (pt) | 2017-08-22 |
| BR112016029157A8 (pt) | 2021-07-06 |
| US10556942B2 (en) | 2020-02-11 |
| EP3155009A1 (en) | 2017-04-19 |
| AU2015273049A1 (en) | 2017-01-12 |
| CA2951766A1 (en) | 2015-12-17 |
| JP2017521389A (ja) | 2017-08-03 |
| PH12016502482A1 (en) | 2017-04-10 |
| CN106536565A (zh) | 2017-03-22 |
| WO2015189832A1 (en) | 2015-12-17 |
| AU2015273049B2 (en) | 2019-11-14 |
| RU2698654C2 (ru) | 2019-08-28 |
| MA40232A (fr) | 2017-04-19 |
| US20170152298A1 (en) | 2017-06-01 |
| JP6747985B2 (ja) | 2020-08-26 |
| RU2017100005A (ru) | 2018-07-13 |
| RU2017100005A3 (enExample) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016502482A1 (en) | Process for the purification of tnfr:fc fusion protein | |
| PH12020550205A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
| MX2023008559A (es) | Proteínas de fusión fc heterodiméricas il15/il15ra. | |
| PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
| PH12020550927A1 (en) | Therapeutic enzyme fusion protein having novel structure and use thereof | |
| EP4335874A3 (en) | Anti-hla-g antibodies and use thereof | |
| EP4299595A3 (en) | Compositions and methods related to engineered fc constructs | |
| MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| MX2022009875A (es) | Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes. | |
| MX384346B (es) | Bloqueo de cd73. | |
| MX358137B (es) | Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso. | |
| MX391632B (es) | Proteasa de cisteína. | |
| ZA201705113B (en) | Cysteine protease | |
| MX375524B (es) | Anticuerpos anti-axl. | |
| SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| SG10201907582WA (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
| WO2017015622A8 (en) | Gdf11 binding proteins and uses thereof | |
| SG10201908028SA (en) | Cyclopropylamines as lsd1 inhibitors | |
| WO2016061389A3 (en) | Anti-alpha-synuclein antibodies and methods of use | |
| IN2014DN08721A (enExample) | ||
| AU2017317563A8 (en) | Detergent compositions comprising xanthan lyase variants I | |
| PH12020500054A1 (en) | Novel therapeutic enzyme fusion protein and use thereof | |
| MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| MX2024000004A (es) | Proteinas de fusion de inhibidor de tripsina urinaria (uti). |